ISSN (Online) 2456 -1304

International Journal of Science, Engineering and Management (IJSEM)
Vol 4, Issue 1, January 2019

Utilization of Big Data Analysis in Biomedicinal Chemistry

Jeenat Aslam
Department of Chemistry
College of Science, Yanbu-30799, Taibah University, Al-Madina, Saudi Arabia

Abstract: **-- The rising amount of biomedical information in chemistry and life sciences needs the progress of latest techniques and viewpoint for their use. Now in this manuscript, we shortly talk about various dares and chance of this high-speed increasing region of investigate with center of attention on those to be inscribed within the BIGCHEM plan. The manuscript begins with a short explanation of various obtainable assets for "Big Data" in chemistry and analysis of the significance of information value. The 'big data' idea acts a gradually more significant part in numerous scientific fields. The Big data requires more than remarkable high volumes of information that turn into existing. Diverse basis distinguishing big data must be cautiously calculated in computational information mining, as we talk about herein concentrating on medicinal chemistry. It is a logical regulation where big data is starting to appear and give latest chances. For paradigm, the various medicines capacity to exclusively act together with numerous objects, described as promiscuity, forms the molecular origin of polypharmacology, a warm subject in drug finding. We explain that the able examination of billions of molecules needs the growth of smart plans. Furthermore, the problem of protected data giving out without reveals chemical form which is vital to permit bi-party or multi-party information distribution. Information giving out is significant in the situation of the modern development of "open innovation" in pharmaceutical trade, which has led to not merely more data distribution between academics and pharma companies but also the known as "precompetitive" teamwork among pharma companies. At the conclusion we emphasize the significance of learning in "Big Data" for additional growth of this field.**

Keywords: **-- Drug delivery; Computational; Big data; Big data promiscuity; Polypharmacology Medicinal chemistry.**

I. INTRODUCTION

Wikipedia depict "Big Data"[1] is a word for information sets that are so vast or complex that conservative data giving out approach are insufficient also features that not merely the dimension but also the information difficulty is extremely main. Business analyst D Laney (in 2001) connected 'big data' with required handling the volume, velocity and variety of information [2]. The volume, velocity and variety signify the often-cited '3Vs' of big data. In pharmaceutical investigated district, "Big Data" is promising from the quickly increasing genomics information gratitude to the fast growth of gene sequencing skill. Over the last decade there really has been a notable raise in the quantity of obtainable compound action and biomedical information [3–5]. Big data feature characteristic is that conservative information giving out, collection and transport framework are inadequate for management such records. Furthermore, big data might be prepared to changeable levels or even be totally formless. Significantly, big information features exit a large amount outside the industrial stage and technical big information basis must be cautiously measured when sketching conclusions from information examination [6]. How to resourcefully taking out the big range of information in chemistry becomes a significant difficulty for the upcoming chemical manufacturing development together with pharmaceutical, agrochemical, biotechnological, fragrances, and common chemical industries. Big Data composed from literature typically are fairly loud and the reasons are multiple. Primary, this might be owing to the biological examined itself, for illustration unique research errors, evaluate artifacts in viewing etc. Secondly, there an ordinary way lack for annotating biological endpoints, achievement approach and goal identifier. Thirdly, incorrectly survive at what time extracting information values, units and/or chemical name appreciation for regular literature taking out. Big information arises from biology has furthermore posted drug detection [7,8], where it is accompanied with, for paradigm, information from high-throughput screens, group test, imaging, pharmacology and medical experiments, which – at least in division – also have big information distinctiveness by at present. These evolution significantly dare drug finding environments and consequence in the require to investigate novel development ideas for finding scientists, additional highlight interdisciplinary appeals, and place information science to the drug discovery-relevant control spectrum [8]. A significant position to highlight is that our conversation of big data matter in medicinal

ISSN (Online) 2456 -1304

International Journal of Science, Engineering and Management (IJSEM)
Vol 4, Issue 1, January 2019

chemistry mainly target on investigational information, which characteristically need computational study – but not on computationally created data. If we get into kindness that accurately thousands of chemical legends and properties can be considered for several known compound, it is obvious that the compound-identify information quantity can be additional enlarged via magnitude instructions through computational chemistry. Although, such 'theoretical' big information shows a different group to which big data standard measured herein merely unclearly relate and usefulness of which – and significance carry out of medicinal chemistry – might too be questioned. Investigating compound promiscuity as the molecular origin of polypharmacology gives an exciting use for appears big information in medicinal chemistry. This is the case because views relating to the possible extent of promiscuity and polypharmacology extensively vary in the field and are frequently expressed on the origin of instinct or slanted viewpoint [9], lacking watchfully in view of obtainable action records [10]. With the big data beginning in medicinal chemistry, chances raise to appear at quantitative promiscuity evaluate that are retreat by statistically important information volumes. This giving target on rising big records concern in medicinal chemistry and exhibited how big data norm impact the investigation of compound action statistics. Mainly devise as a perspective-type object, it was considered to be 'data-driven,' dependable with its chief topic. Therefore, we purposely merge the big data features conversation, excellent research and private viewpoints with a major study of compound action information, ensuing in a viewpoint with investigate mechanism. For causes considered over, promiscuity investigation was selected as a very good theme for compound information taking out to observe likely series of multitarget actions, as information volumes especially raise, and reconsider earlier promiscuity evaluate in an exact way.

Data repositories

Three community area databases were used as information origin as well as ChEMBL (release 22; ChEMBL22) [11,12], [Fig. 1] the main depository for compounds and action data from medicinal chemistry literature and patent origin, PubChem BioAssay [13], the main depository for viewing information, and DrugBank (version 5.0.3) [14], inclusive basis of standard and investigational drugs. The entire qualifying compounds structures from dissimilar information sources were consistent by the Open Eye OEChem toolkit [15]. Canonical simplified molecular input line-entry system (SMILES) strings [30], were created to chart compounds crossways dissimilar database. ChEMBL provides two interior mathematical directory systems as aim identifiers as well as 'tid' and 'CHEMBL_ ID.' Targets from PubChem are chosen by gene identifiers. For objective comments in Drug Bank, UniProt IDs [16], are specified. To regulate targets from diverse origin and plan them, UniProt IDs were selected as the object identifiers. Therefore, aim selection in ChEMBL and PubChem were transformed to UniProt IDs (if obtainable) by the ID mapping purpose of ChEMBL or UniProt. Systematic associations among compounds were analytically investigated via appealing the matched molecular pair (MMP) formalism [17]. An MMP is usually distinct as a couple of compounds that merely vary through a chemical modify at a solitary place [18], in other terms, a couple of underneath switch, termed a 'chemical transformation' [19]. Earlier distinct alteration dimension limits were functional to imprison MMPs to structural analogs pairs [20]. MMPs were designed by a domestic report of a disintegration algorithm [21] utilizing the Open Eye toolkit [17].



Figure 1. Information origin desegregated into the Open PHACTS finding platform.

For every compound, its 'promiscuity degree' (PD) was distinct as the figure of targets a compound is recognized to be lively against. It is designed as the sum digit of aim comments obtainable at a known point in time. Compounds for which merely a particular aim was accessible (PD 1) were classified as objective exact. In addition, for compounds from ChEMBL and drugs mapped to ChEMBL, the PDs development was ovserbed in excess of time from 1995 to 2015 on the basis of ChEMBL action data and publishing dates removed from them. Profitable databases, like as SciFinder, GOSTAR and Reaxys have assembled a huge quantity of information composed from publications and patent data.

ISSN (Online) 2456 -1304

International Journal of Science, Engineering and Management (IJSEM)
Vol 4, Issue 1, January 2019

Data feature and examination of chemical liberty

The feature and dense illustration of millions of compounds (like as >110M compounds in SciFinder), which is frequently primary step of information study, represents important confront in Big Data analysis. It is regularly complete via analytical huge compound assembly into a small size gap, agreeable to illustration examination and instinctive study by the human brain. It could help to observe chemical organizations with new chemical scaffolds and physicochemical properties (e.g., for compound records plan), to contrast dissimilar libraries or to recognize parts of chemical space that acquire convinced pharmacological outline [21]. The extremely high-quality approaches like as principle component analysis (PCA), [22] Generative Topographic Mapping (GTM), [23] Kohonen networks, [24] Diffusion Maps, [25] and interactive maps acquired through high-dimensional descriptor spaces projection,[26,27] are shows potential skills in this circumstance. Such hallucination techniques can be also utilized to understand structure-activity associations [28]. For illustration, in the "Stargate" description of GTM, latent space associations two diverse preliminary spaces – one distinct by molecular descriptor and another one by investigational behavior [29]. This allows, on one hand, to expect the entire pharmacological outline for one exacting chemical construction and, on the other hand, to recognize novel construction equivalent to the known outline. a new paradigm of investigate chemical gap is by a so called Chem GPS offer to symbolize and find the way through drug-like [30] and pharmacokinetic [31] chemical space based on PCA components removed from molecular 2D descriptors. Their alternatives Chem GPS-NP [32] feature the natural product gap in distinct. It has been revealed that the correctness of relating molecules in Chem GPS-NP distinct gap is alike to the structural fingerprints precision in recovering bioactive molecules [33].

Structure-activity association modeling

Earlier to concentrating on quantitative evaluation of drugs promiscuity and bioactive compounds through information removal, we shortly evaluation earlier observations that have described computational devices and information form for promiscuity research or additional main data removing study. For illustration, ChEMBL Space graphical explorer, a standalone Java implementation, was evolved to produce and imagine compound based object networks on the basis of ChEMBL action data and recognize compounds with sought after multitarget activity profiles [34]. A connected Web based study device described Pharma Trek was imported to mine multitarget activity gap by determine, for illustration, the targets pool and power thresholds of compounds vigorous beside these targets [35]. Consequently, Pharma Trek was functional to ChEMBL to imagine compound activity profiles. A further Web-based resource was described to take out compound activity counts from PubChem assessment and analyze a variety of compound descriptors for following study [36]. Also, for migrating and analyzing PubChem test information, the Bio analyzed investigate record arrangement was developed that also incorporated an amount of information mining and idea tools [37]. Furthermore, for drugs, the PROMISCUOUS record was imported compose 25,000 access also counting investigational drugs and drugs reserved from the market. In addition, 21,500 drug–target connections and 104,000 drugs based protein–protein associations were assemble from community funds by text and information mining and manually curate [38]. Object and drugs consequence profiles were then create in set of connections depictions that captured associations among drugs and target proteins and among drugs and consequences. The computational devices reported over help in compound information and data removal from main repositories.

Information distribution and records protection

Even huge pharma companies can build up simply partial amounts of applicable assets data. As it was mentioned previous to, distribution information composed through dissimilar firms provides the chance to expand computational models on to a great extent larger information origin, thus rising model strength, accuracy and chemical space coverage [39,40]. The growth of attitudes to expect ADME/T properties in a mutual way is attractive fraction of potential pharma R&D plans. Newly, AstraZeneca and Bayer complete attempts to evaluate their whole compound gathering in a protected way [41] although AstraZeneca and Roche found the information distribution association on the subject of coordinated molecular sets to get better metabolism, pharmacokinetics, and protection of their compounds through MedChemica [42]. Furthermore, AstraZeneca has previously give a number of its ADMETox information to CheMBL.[43] However, mutual hard work in this field are usually not simple. Logical possessions features connected with confidential compound assembly and linked information might be applicable for continuing drug finding attempts. Protected combined computation techniques based on current encryption hypothesis [44,45] give behavior to expand models lacking the require to split molecular structures or proprietary molecular depiction.

ISSN (Online) 2456 -1304

International Journal of Science, Engineering and Management (IJSEM)
Vol 4, Issue 1, January 2019

These approaches are compute-intense and bandwidth-demanding but quick growth of Internet and growing computational influence of computers is production them related to actual world troubles [46,47]. Preparation big information scientists – A Chemoinformaticians

The challenges of "Big Data" need efficiently skilled authority, "chemistry information scientists" – the chemoinformaticians, who can manage with the difficulty and troubles variety in the scientific finding field. Conservative "information scientists" approaching from computer science field, as well as computational chemists with small awareness in computer science, are enormously doubtful to have enough information and skill to contact both chemoinformatics queries and will require extra preparation. Main queries in this view are subsequent ones: How should one equilibrium chemistry and computer science preparation? How should one make sure an elevated plane of scientific skill and, at the similar moment, an almost leaning state of mind? Which latest and fast increasing methodologies should be measured? How should one get ready trainees to effort at the boundary among computing chemistry, and pharmaceutical study? These questions can be explained merely through secure connections of intellectual associates and the end-users and rigid connection of industrial associates in targeted investigate trainings. In this respect the guidance plans, like as obtainable during Marie Skłodowska-Curie events, give liberal hold carry via Innovative Training Networks means, which promote and endorse such kind of relations.

Analytics benefits in the chemical industry

Smart built-up can advantage chemical companies in numerous ways like:

Anticipatory protection and benefit organization: The chemical industry tools such as turbines and compressors are connected with sensors that carry in a nonstop information stream. These data are used by analytics to discover arrangement and predict possible disruption and discontinue machinery failures. In the same way, information association from identical apparatus can be used by chemical industries to assurance presentation optimization. Therefore, chemical industry firms can keep away from unexpected machine shut-downs and development their efficiency.

Finding of alarms: The chemicals that the chemical industry compact with are extremely dengerous. Accordingly, in the chemical industry, it is extremely significant to constantly path the creation, cache and the chemicals carrying. Analytics will assist chemical industries to capably observe and lesser the gases hazardous level, such as oxygen, hydrogen, sulfide, sulfur dioxide, carbon monoxide, and nitrogen dioxide. This will remove several accidents or blast that could reason injure to belongings and existence.

Power organization: several vital action are carry out concurrently in a chemical plant; it becomes complex to choose most favorable controlling circumstances. Smart built-up techniques and superior analytics create employ of technologies like soft sensors, which can help in dispensation a number of information points. To get better power effectiveness, they also permit organize of the substandard procedure. This method, cencern in the chemical industry can not merely assurance power competence but will also assist them in decreasing their expenses.

Prediction of phase diagram: Phase diagram presentation situation at which thermodynamically different phases arise and coexist at balance can be predicted by computer codes. Anticipatory protection and benefit organization: Sensors on equipment such as turbines, compressors, carry in a nonstop stream of information which analytics makes employ of to recognize patterns and expect possible breakdowns and avoid machinery failures. Furthermore, information contrast from related equipment can be used for concert optimization.

Forecasting of load: It is essentially the capability to load predict for rare resources (oil, natural gas, air, water, metals, minerals, etc.) to assemble insist and provide of energy and power. Security organization: conventional security methods engaged the compilation and samples testing whereas manufacturing 4.0 technologies build employ of methods that observe immediate information. For example, mechanical vibrations or cracks in a chemical boiler can be sensed via piezoelectric composite paints thereby decreasing manufacture risks.

II. CONCLUSION

Medicinal chemistry is noticing the start of the big information generation, which biology already listed more than a decade ago, due to the accessibility of high-throughput genomics technologies. In medicinal chemistry, which is an essential fraction of drug finding and usually a conventional scientific regulation, big information mainly include quickly rising figures of compounds and volumes of connected movement information. Herein, we have discussed significant big information benchmark as well as

information heterogeneity, difficulty and assurance that – in addition to simple data volumes – play an important task in employing big information and knowledge from it. The computational study of drugs promiscuity and further bioactive compounds as the molecular origin of polypharmacology was chosen as an informative illustration of how big information impacts and dares investigate in medicinal chemistry. Mutually manufacturing and educational associates divide elevated prospect from "Big Data" in chemistry, which is a novel rising district of investigate on the limits of numerous regulations. The proceeds in this region require growth of latest computational perspective and further significantly learning of scientists, who will more development this field.

Future point of view

As the medicinal chemistry practice is immediately opening to skill big information phenomena; it is obvious that big data will take part in more and more significant function going onward. Additional big data awareness matter and possible caution will still require to be increased to absolutely contact the fled. For paradigm, although quite clear, chance given by accompanying domestic chemical optimization labors with community field SAR information are not yet extensively valued, while they should be regularly careful. Absorbing outside information – and facts resulting from such information – into finding projects and judgment creation dares medicinal chemistry applications. The big data uniqueness more complicates matters. Promiscuity examination serves as a superior illustration. At present, multi objective tiny molecules actions and their possible usefulness or disadvantage for drug finding are still just small tacit. Especially, determining concerning the promiscuity scale between drugs and applicant compounds is frequently greatly expose to assumption and slanted sights than exact scientific evaluation. Scientists complicated to examine, big information provide a beautiful chance for further comprehensive scientific molecular promiscuity evaluation in drug finding. As we have verified herein, a situation is far from being easy and exact information investigation, watchfully attractive big information criteria into deliberation, provides as a lot of novel questions as insights. What we can definitely finish on at present accessible compound activity information origin is that standard drugs are on regular much more immoral than other bioactive compounds and bioactive compounds are generally fewer immoral than frequently unspecified. Some further prospective or opportunity are not retreat through consistent information and affect the area of assumption. From watchful information mining and investigation, latest query happen. While we have revealed, an assortment of construction promiscuity associations can be experiential. Are these associations 'actual' or mainly resolved via experimental parameters and the mode information is developed? Also, might it eventually be likely to study the molecular words that immoral compounds and object employ in connecting with each other and respectively plan compounds with preferred multitarget behavior? If so, how might polypharmacology-driven drugs efficiency and unnecessary surface belongings is impartial? Evidently, dealing with big compound information and knowledge from these information will also give initial marks for assume novel experimentally conclusive assumption with possible for stimulating prospect study, which – after every – is fine reports for science.

REFERENCES

[1] https://en.wikipedia.org/wiki/Bigdata (10June 2016)

[2] https://blogs.gartner.com

[3] B. Chen, A. J. Butte, Clin. Pharmacol. Ther. 2016, 99, 285 – 297.

[4] S. Kim, P. A. Thiessen, E. E. Bolton, J. Chen, G. Fu, A. Gindulyte, L. Han, J. He, S. He, B. A. Shoemaker, J. Wang, B. Yu, J. Zhang, S. H. Bryant, Nucleic Acids Res. 2016, 44, D1202 – 1213.

[5] G. Papadatos, A. Gaulton, A. Hersey, J. P. Overington, J. Comput. Aided. Mol. Des. 2015, 29, 885 – 896

[6] I. V. Tetko, D. Lowe, A. J. Williams, J. Cheminform. 2016, 8, 2

[7] Al-Lazikani B, Workman P. Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome. Future Med. Chem. 8(14), 1711–1716 (2016).

[8] Bajorath J, Jenkins J, Overington J, Walters WP. Drug discovery and development in the era of big data. Future Med. Chem. 8(15), 1807–1813 (2016)

[9] Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery: miniperspective. J. Med. Chem. 57(19), 7874–7887 (2014).

[10] Hu Y, Bajorath J. How promiscuous are pharmaceutically relevant compounds? A data-driven

assessment. AAPS J. 15(1), 104–111 (2013).

[11] Gaulton A, Bellis LJ, Bento AP et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100–D1107 (2012).

[12] Gaulton A, Hersey A, Nowotka M et al. The ChEMBL database in 2017. Nucleic Acids Res. 45(D1), D945–D954 (2017).

[13] Wang Y, Xiao J, Suzek TO et al. PubChem's BioAssay database. Nucleic Acids Res. 40, D400–D412 (2012).

[14] Law V, Knox C, Djoumbou Y et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091–D1097 (2014) a

[15] OEChem TK. OpenEye Scientifc Software, Inc., NM, USA (2012). www.eyesopen.com/

[16] Weininger D. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J. Chem. Inf. Comput. Sci. 28(1), 31–36 (1988)

[17] UniProt Consortium. The Universal Protein Resource (UniProt) in 2010. Nucleic Acids Res. 38, D142–D148 (2010).

[18] Kenny PW, Sadowski J. Structure modifcation in chemical databases. In: Chemoinformatics in Drug Discovery. Oprea TI (Ed.). Wiley-VCH, Weinheim, Germany, 271–285 (2004).

[19] Hussain J, Rea C. Computationally effcient algorithm to identify matched molecular pairs (MMPs) in large data sets. J. Chem. Inf. Model. 50(3), 339–348 (2010).

[20] Hu X, Hu Y, Vogt M, Stumpfe D, Bajorath J. MMP-cliffs: systematic identifcation of activity cliffs on the basis of matched molecular pairs. J. Chem. Inf. Model. 52(5), 1138–1145 (2012)

[21] M. Reutlinger, G. Schneider, J. Mol. Graph. Model. 2012, 34, 108–117.

[22] M. Feher, J. M. Schmidt, J. Chem. Inf. Comput. Sci. 2003, 43, 218–227.

[23] H. A. Gaspar, G. Marcou, D. Horvath, A. Arault, S. Lozano, P. Vayer, A. Varnek, J. Chem. Inf. Model. 2013, 53, 3318–3325.

[24] P. Schneider, K. Stutz, L. Kasper, S. Haller, M. Reutlinger, F. Reisen, T. Geppert, G. Schneider, Pharmaceuticals 2011, 4.

[25] N. V. Kireeva, S. I. Ovchinnikova, I. V. Tetko, A. M. Asiri, K. V. Balakin, A. Y. Tsivadze, ChemMedChem 2014, 9, 1047–1059.

[26] L. Ruddigkeit, M. Awale, J. L. Reymond, J. Cheminform. 2014, 6, 27.

[27] M. Awale, J. L. Reymond, J. Chem. Inf. Model. 2015, 55, 1509– 1516.

[28] M. Reutlinger, W. Guba, R. E. Martin, A. I. Alanine, T. Hoffmann, A. Klenner, J. A. Hiss, P. Schneider, G. Schneider, Angew. Chem. Int. Ed. Engl. 2011, 50, 11633–11636.

[29] H. A. Gaspar, Baskin, II, G. Marcou, D. Horvath, A. Varnek, J. Chem. Inf. Model. 2015, 55, 2403–2410.

[30] T. I. Oprea, J. Gottfries, J. Comb. Chem. 2001, 3, 157–166.

[31] T. I. Oprea, I. Zamora, A. L. Ungell, J. Comb. Chem. 2002, 4, 258–266.

[32] J. Larsson, J. Gottfries, S. Muresan, A. Backlund, J. Nat. Prod. 2007, 70, 789–794.

[33] R. Buonfiglio, O. Engkvist, P. Varkonyi, A. Henz, E. Vikeved, A. Backlund, T. Kogej, J. Chem. Inf. Model. 2015, 55, 2375–2390

[34] Fechner N, Papadatos G, Evans D et al. ChEMBLSpace – a graphical explorer of the chemogenomic space covered by the ChEMBL database. Bioinformatics 29(4), 523–524 (2013).

[35] Carrascosa MC, Massaguer OL, Mestres J. PharmaTrek: a semantic web explorer for open innovation in multitarget drug discovery. Mol. Inform. 31(8), 537–541 (2012).

[36] Canny SA, Cruz Y, Southern MR, Griffn PR. PubChem promiscuity: a web resource for gathering compound

promiscuity data from PubChem. Bioinformatics 28(1), 140–141 (2012).

[37] Howe EA, de Souza A, Lahr DL et al. BioAssay Research Database (BARD), chemical biology and probe-development enabled by structured metadata and result types. Nucleic Acids Res. 43, D1163–D1170 (2015).

[38] Von Eichborn J, Murgueitio MS, Dunkel M, Koerner S, Bourne PE, Preissner R. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res. 39, D1060–D1066 (2011).

[39] Roche and AstraZeneca launch medicinal chemistry data-sharing consortium to further accelerate drug discovery. http://www.roche-nutley.com/home/press-releases/june-26–2013.html (10 June 2016).

[40] R. Chaguturu, Collaborative innovation in drug discovery: Strategies for public and private partnerships, 2014.

[41] T. Kogej, N. Blomberg, P. J. Greasley, S. Mundt, M. J. Vainio, J. Schamberger, G. Schmidt, J. Huser, Drug Discov. Today 2013, 18, 1014 – 1024.

[42] I. V. Tetko, R. Abagyan, T. I. Oprea, J. Comput. Aided. Mol. Des. 2005, 19, 749–764.

[43] Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds. http://dx.doi.org/10.6019/CHEMBL3301361 (6 June 2016).

[44] A. F. Karr, J. Feng, X. Lin, A. P. Sanil, S. S. Young, J. P. Reiter, J. Comput. Aided. Mol. Des. 2005, 19, 739–747.

[45] R. Cramer, I. Damgaard, J. B. Nielsen, Secure multiparty computation : an information theoretic approach, Cambridge University Press, Cambridge ; New York, 2015.

[46] R. Bendlin, I. Damg rd, C. Orlandi, S. Zakarias, in Proceedings of the 30th Annual international conference on Theory and applications of cryptographic techniques: advances in cryptology, Springer-Verlag, Tallinn, Estonia, 2011, pp. 169–188.

[47] R. Agrawal, R. Srikant, SIGMOD Record (ACM Special Interest Group on Management of Data) 2000, 29, 439–450.